Human Genome kept at neutral by Merrill

Human Genome Sciences Inc. maintained its neutral rating by Merrill Lynch analyst Hari Sambasivam. The company reported revenues of $9.3 million compared to Merrill's estimate of $1.2 million. During the quarter, Human Genome recognized a milestone payment (undisclosed amount) from GlaxoSmithKline relating to Albuferon development and a $1.5 million payment from the U.S. government related to ABthrax. Shares of the Rockville, Md., biopharmaceutical company were down 52 cents, or 4.71%, at $10.52 on volume of 3,042,960 shares versus the three-month running average of 3,042,960 shares. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.